HSP90AA1 and myeloid sarcoma: The hUC‐MSCs treatment significantly diminished supernatant concentrations of interferon‐γ, tumor necrosis factor‐α, interleukin (IL)‐4, and IL‐17 in SLE‐MS group, as well as inhibited HSP90AA1 in the glucose‐activated PI3K‐AKT pathway.